Compare BZUN & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZUN | XGN |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.7M | 74.6M |
| IPO Year | N/A | 2014 |
| Metric | BZUN | XGN |
|---|---|---|
| Price | $2.48 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 235.0K | ★ 315.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.10 | $20.99 |
| Revenue Next Year | $3.93 | $11.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $2.80 |
| 52 Week High | $4.88 | $12.23 |
| Indicator | BZUN | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 37.22 |
| Support Level | N/A | $3.15 |
| Resistance Level | $3.05 | $4.00 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 31.78 | 29.59 |
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.